{"id":"combination-product-trastuzumab-pertuzumab","safety":{"commonSideEffects":[{"effect":"Diarrhoea","drugRate":"66.5%","placeboRate":"","totalAtRisk":1678,"totalAffected":1116,"trialsReporting":3},{"effect":"Alopecia","drugRate":"47.0%","placeboRate":"","totalAtRisk":1678,"totalAffected":788,"trialsReporting":3},{"effect":"Nausea","drugRate":"37.1%","placeboRate":"","totalAtRisk":1678,"totalAffected":623,"trialsReporting":3},{"effect":"Fatigue","drugRate":"30.9%","placeboRate":"","totalAtRisk":1678,"totalAffected":519,"trialsReporting":3},{"effect":"Asthenia","drugRate":"28.8%","placeboRate":"","totalAtRisk":1678,"totalAffected":483,"trialsReporting":3},{"effect":"Anaemia","drugRate":"23.9%","placeboRate":"","totalAtRisk":1678,"totalAffected":401,"trialsReporting":3},{"effect":"Rash","drugRate":"23.8%","placeboRate":"","totalAtRisk":1678,"totalAffected":399,"trialsReporting":3},{"effect":"Vomiting","drugRate":"23.6%","placeboRate":"","totalAtRisk":1678,"totalAffected":396,"trialsReporting":3},{"effect":"Arthralgia","drugRate":"22.6%","placeboRate":"","totalAtRisk":1678,"totalAffected":379,"trialsReporting":3},{"effect":"Headache","drugRate":"21.8%","placeboRate":"","totalAtRisk":1678,"totalAffected":366,"trialsReporting":3},{"effect":"Neuropathy peripheral","drugRate":"21.6%","placeboRate":"","totalAtRisk":1678,"totalAffected":362,"trialsReporting":3},{"effect":"Pruritus","drugRate":"19.2%","placeboRate":"","totalAtRisk":1678,"totalAffected":322,"trialsReporting":3},{"effect":"Mucosal inflammation","drugRate":"19.1%","placeboRate":"","totalAtRisk":1678,"totalAffected":320,"trialsReporting":3},{"effect":"Decreased appetite","drugRate":"18.6%","placeboRate":"","totalAtRisk":1678,"totalAffected":312,"trialsReporting":3},{"effect":"Myalgia","drugRate":"18.4%","placeboRate":"","totalAtRisk":1678,"totalAffected":309,"trialsReporting":3},{"effect":"Cough","drugRate":"18.4%","placeboRate":"","totalAtRisk":1678,"totalAffected":308,"trialsReporting":3},{"effect":"Oedema peripheral","drugRate":"17.9%","placeboRate":"","totalAtRisk":1678,"totalAffected":300,"trialsReporting":3},{"effect":"Epistaxis","drugRate":"17.1%","placeboRate":"","totalAtRisk":1678,"totalAffected":287,"trialsReporting":3},{"effect":"Pyrexia","drugRate":"16.7%","placeboRate":"","totalAtRisk":1678,"totalAffected":281,"trialsReporting":3},{"effect":"Constipation","drugRate":"15.9%","placeboRate":"","totalAtRisk":1678,"totalAffected":267,"trialsReporting":3},{"effect":"Neutropenia","drugRate":"15.2%","placeboRate":"","totalAtRisk":1678,"totalAffected":255,"trialsReporting":3},{"effect":"Back pain","drugRate":"15.0%","placeboRate":"","totalAtRisk":1678,"totalAffected":252,"trialsReporting":3},{"effect":"Stomatitis","drugRate":"14.3%","placeboRate":"","totalAtRisk":1678,"totalAffected":240,"trialsReporting":3},{"effect":"Paraesthesia","drugRate":"14.2%","placeboRate":"","totalAtRisk":1678,"totalAffected":239,"trialsReporting":3},{"effect":"Dizziness","drugRate":"13.9%","placeboRate":"","totalAtRisk":1678,"totalAffected":234,"trialsReporting":3},{"effect":"Pain in extremity","drugRate":"13.2%","placeboRate":"","totalAtRisk":1678,"totalAffected":222,"trialsReporting":3},{"effect":"Abdominal pain","drugRate":"13.2%","placeboRate":"","totalAtRisk":1678,"totalAffected":221,"trialsReporting":3},{"effect":"Dyspnoea","drugRate":"13.2%","placeboRate":"","totalAtRisk":1678,"totalAffected":221,"trialsReporting":3},{"effect":"Muscle spasms","drugRate":"13.4%","placeboRate":"","totalAtRisk":1563,"totalAffected":210,"trialsReporting":2},{"effect":"Urinary tract infection","drugRate":"12.5%","placeboRate":"","totalAtRisk":1678,"totalAffected":210,"trialsReporting":3},{"effect":"Nasopharyngitis","drugRate":"12.5%","placeboRate":"","totalAtRisk":1563,"totalAffected":196,"trialsReporting":2},{"effect":"Insomnia","drugRate":"10.9%","placeboRate":"","totalAtRisk":1678,"totalAffected":183,"trialsReporting":3},{"effect":"Dry skin","drugRate":"10.7%","placeboRate":"","totalAtRisk":1678,"totalAffected":180,"trialsReporting":3},{"effect":"Upper respiratory tract infection","drugRate":"10.7%","placeboRate":"","totalAtRisk":1678,"totalAffected":180,"trialsReporting":3},{"effect":"Lacrimation increased","drugRate":"11.4%","placeboRate":"","totalAtRisk":1563,"totalAffected":178,"trialsReporting":2},{"effect":"Nail disorder","drugRate":"10.5%","placeboRate":"","totalAtRisk":1678,"totalAffected":176,"trialsReporting":3},{"effect":"Hypertension","drugRate":"11.1%","placeboRate":"","totalAtRisk":1563,"totalAffected":174,"trialsReporting":2},{"effect":"Abdominal pain upper","drugRate":"10.1%","placeboRate":"","totalAtRisk":1678,"totalAffected":170,"trialsReporting":3},{"effect":"Ejection fraction decreased","drugRate":"10.9%","placeboRate":"","totalAtRisk":1563,"totalAffected":170,"trialsReporting":2},{"effect":"Dyspepsia","drugRate":"9.7%","placeboRate":"","totalAtRisk":1678,"totalAffected":163,"trialsReporting":3},{"effect":"Dysgeusia","drugRate":"9.9%","placeboRate":"","totalAtRisk":1551,"totalAffected":154,"trialsReporting":2},{"effect":"Bone pain","drugRate":"9.7%","placeboRate":"","totalAtRisk":1563,"totalAffected":151,"trialsReporting":2},{"effect":"Hot flush","drugRate":"8.5%","placeboRate":"","totalAtRisk":1678,"totalAffected":142,"trialsReporting":3},{"effect":"Peripheral sensory neuropathy","drugRate":"8.3%","placeboRate":"","totalAtRisk":1678,"totalAffected":139,"trialsReporting":3},{"effect":"Musculoskeletal pain","drugRate":"8.9%","placeboRate":"","totalAtRisk":1563,"totalAffected":139,"trialsReporting":2},{"effect":"Erythema","drugRate":"9.5%","placeboRate":"","totalAtRisk":1436,"totalAffected":137,"trialsReporting":1},{"effect":"Oropharyngeal pain","drugRate":"8.6%","placeboRate":"","totalAtRisk":1436,"totalAffected":124,"trialsReporting":1},{"effect":"Weight decreased","drugRate":"7.3%","placeboRate":"","totalAtRisk":1678,"totalAffected":122,"trialsReporting":3},{"effect":"Onycholysis","drugRate":"8.2%","placeboRate":"","totalAtRisk":1436,"totalAffected":118,"trialsReporting":1},{"effect":"Influenza","drugRate":"7.4%","placeboRate":"","totalAtRisk":1563,"totalAffected":116,"trialsReporting":2}]},"_chembl":null,"_fixedAt":"2026-03-30T11:30:51.833284","allNames":"combination product: trastuzumab + pertuzumab","_dailymed":null,"mechanism":{"target":"HER2","drugClass":"HER2 inhibitors","explanation":"This combination therapy works by using two different monoclonal antibodies to bind to the HER2 receptor, which helps prevent cancer cells from growing and dividing. By targeting HER2 from multiple angles, the drugs enhance the inhibition of the HER2 signaling pathway.","oneSentence":"Trastuzumab and pertuzumab target HER2, blocking signal transduction pathways that promote tumor growth and survival."},"_scrapedAt":"2026-03-28T00:43:58.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:37:24.847974+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":"Breast Cancer, Solid Tumor","enrollment":200},{"nctId":"NCT07053085","phase":"PHASE2","title":"A Study of Surgery and Radiotherapy in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-09-17","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":162},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT07416409","phase":"","title":"Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Deraya University","startDate":"2023-06-10","conditions":"Breast Neoplasms, Oncology, HER2-positive Breast Cancer","enrollment":80},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT02320435","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-02-02","conditions":"Solid Tumors","enrollment":154},{"nctId":"NCT07402473","phase":"PHASE2","title":"EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-03-01","conditions":"HER2-positive Early-stage Breast Cancer","enrollment":50},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07386938","phase":"PHASE3","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-09","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT07340398","phase":"PHASE2","title":"Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-25","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT00781612","phase":"PHASE2","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2008-10-16","conditions":"Neoplasm Metastasis","enrollment":720},{"nctId":"NCT04538742","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-28","conditions":"Metastatic Breast Cancer","enrollment":245},{"nctId":"NCT07246317","phase":"PHASE2","title":"Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT05954143","phase":"PHASE2","title":"Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Bolt Biotherapeutics, Inc.","startDate":"2023-11-30","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":11},{"nctId":"NCT04108858","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":2},{"nctId":"NCT05385705","phase":"PHASE1","title":"A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020","status":"TERMINATED","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2022-05-11","conditions":"Breast Neoplasms","enrollment":2},{"nctId":"NCT07129018","phase":"PHASE2","title":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-11","conditions":"Biliary Tract Cancer (BTC), First-line Therapy","enrollment":63},{"nctId":"NCT06973525","phase":"PHASE2","title":"This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-01","conditions":"HER2-positive Breast Cancer","enrollment":30},{"nctId":"NCT07003074","phase":"PHASE3","title":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Breast Cancer","enrollment":642},{"nctId":"NCT06927180","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04-16","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":180},{"nctId":"NCT06190600","phase":"NA","title":"Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Greater Poland Cancer Centre","startDate":"2018-10-11","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT05426486","phase":"PHASE2, PHASE3","title":"A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Caigang Liu","startDate":"2022-05-23","conditions":"HER2-positive Breast Cancer","enrollment":136},{"nctId":"NCT05283837","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2022-09-26","conditions":"Metastatic Breast Cancer","enrollment":268},{"nctId":"NCT04629846","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-11-23","conditions":"Breast Cancer","enrollment":517},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT06278870","phase":"PHASE3","title":"Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-09-06","conditions":"HER2-positive Metastatic Breast Cancer, First-line Treatment","enrollment":312},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT03845270","phase":"PHASE2","title":"Her2-positive Lung Cancer Treated With Dedicated Drug","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2019-05-17","conditions":"Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III, HER2 Gene Mutation","enrollment":46},{"nctId":"NCT05983094","phase":"PHASE2","title":"Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-01","conditions":"Breast Cancer, Neoadjuvant Therapy","enrollment":181},{"nctId":"NCT05969184","phase":"PHASE2","title":"Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-12-25","conditions":"Breast Neoplasm Female","enrollment":94},{"nctId":"NCT03988036","phase":"PHASE2","title":"A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2020-08-18","conditions":"Breast Cancer","enrollment":46},{"nctId":"NCT05036005","phase":"PHASE4","title":"Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)","status":"UNKNOWN","sponsor":"Institut fuer Frauengesundheit","startDate":"2021-07-11","conditions":"Breast Cancer, Breast Neoplasms, Breast Cancer Female","enrollment":108},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT04983121","phase":"PHASE2","title":"Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-08-01","conditions":"Breast Neoplasms","enrollment":30},{"nctId":"NCT05483439","phase":"PHASE2","title":"A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2021-10-20","conditions":"Stage II-III Breast Cancer","enrollment":100},{"nctId":"NCT05188313","phase":"PHASE3","title":"TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-03-09","conditions":"Esophageal Cancer, Esophageal Adenocarcinoma","enrollment":376},{"nctId":"NCT02000596","phase":"PHASE2","title":"1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":2},{"nctId":"NCT05188495","phase":"","title":"Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-05-10","conditions":"HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab, Trastuzumab Combined With Pertuzumab and Chemotherapy","enrollment":60},{"nctId":"NCT02073487","phase":"PHASE2","title":"Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2014-02","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT04973319","phase":"PHASE3","title":"Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-08-01","conditions":"Breast Cancer","enrollment":450},{"nctId":"NCT01491737","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02-17","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT01572038","phase":"PHASE3","title":"A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-01","conditions":"Breast Neoplasms","enrollment":1436},{"nctId":"NCT02605915","phase":"PHASE1","title":"Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-31","conditions":"HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer","enrollment":98},{"nctId":"NCT02738970","phase":"PHASE1","title":"A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-23","conditions":"Early Breast Cancer","enrollment":88},{"nctId":"NCT00934856","phase":"PHASE1, PHASE2","title":"A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Breast Cancer","enrollment":98},{"nctId":"NCT01674062","phase":"PHASE2","title":"A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Breast Cancer","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Combination product: Trastuzumab + Pertuzumab","genericName":"combination-product-trastuzumab-pertuzumab","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":5,"trialStats":{"total":14,"withResults":3},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:37:24.847974+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}